To the shareholders, stakeholders, and supporters of BioSig Technologies, Inc.,
As we enter the final weeks of the year, I would like to take this opportunity to reflect on 2020 and its unprecedented challenges. The pandemic has claimed the lives of more than 320,000 Americans, has devastated whole sectors of our economy, has taxed the limits of our nation’s five-star healthcare system, and fundamentally changed the norms of our day-to-day life. My thoughts and prayers are with all of those whose lives were adversely impacted or taken.
Notwithstanding the challenges posed by COVID-19, we at BioSig have stayed focused on our mission, amounting to a year of growth and accomplishments.
In September, we unblinded and published our first human data from the clinical trial for PURE EP™. The trial demonstrated that our system provides physicians with significantly clearer signals: the signals collected with the PURE EP™ System provided, on average, a rate of 36% more information than the conventional systems.
To date, we have installed our technology into seven hospitals, many of which are centers of excellence in electrophysiology and are renowned for their work with new technologies. We are happy to report that 32 physicians have been able to use our technology during more than 410 patient cases whose diagnoses span the entire scope of arrhythmias. The physician feedback we’ve received about our system has been overwhelmingly positive; our website features several impactful case reviews – click here to see Physician Insights.
Earlier this month, our system was featured in the invitation-only educational event, EP Live, a virtual event at the Texas Cardiac Arrhythmia Institute (TCAI). Dr. Andrea Natale used the PURE EP™ System in two real-time patient cases. Since then, TCAI became our first commercial customer with the purchase of 3 PURE EP™ Systems, a commitment that demonstrates the immense promise for our future commercial activities.
Looking at 2021, I can say with confidence that BioSig’s future is bright. In the new year, we will be ramping installations of PURE EP™ in centers nationwide. We expect to sign additional commercial contracts, resulting in consistent and sequential revenue growth. We will also be initiating the process of obtaining the European CE mark in 2021, which, once cleared, will allow us to enter Europe--a continent that accounts for over 20% of the global EP market.
Despite all that 2020 threw at the world, there have been silver linings. BioSig enters 2021 with revenues, promising sales prospects, and our most robust balance sheet to date. We are well-positioned to translate our current momentum to further progress in the new year.
Our warmest wishes for a healthy and peaceful holiday season.
Kenneth L. Londoner
Chairman & CEO, BioSig Technologies, Inc.